Labiotech.eu

vivet therapeutics gene therapy fundraising

News and Trends 4 May 2017

French Gene Therapy Biotech Raises a Huge €37.5M in Series A

Vivet Therapeutics has raised a huge €37.5M in Series A to help bring a new gene therapy technology for rare liver diseases to the clinic. Vivet Therapeutics has managed to attract some of the hottest biotech investors in Europe in its Series A. Led by Novartis Venture Fund and Columbus Venture Partners, and also counting […]

May 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 May 2017

Parent Bacteria Resist Antibiotics Better than their Offspring

According to a new study, a phenomenon known as biased inheritance protects older bacteria from the wrath of antibiotics in low concentrations. Older bacteria in a mixed population of dividing E. coli cells inherit a larger number of drug-expelling membrane proteins and pump out antibiotics better than their younger counterparts in the presence of low […]

May 4, 2017 - 3 minutesmins - By External Contributor

Interview 4 May 2017

This Belgian Startup is building the Next Generation of Diagnostic Tests

DNAlytics changes the diagnosing game. The company builds in vitro diagnosis tests that save many years for patients! I met with Thibault, the founder, to know more about the company. Based in Louvain-La-Neuve, Belgium, DNAlytics develops revolutionary disease diagnostic processes that complement conventional methods. Their main product is RheumaKit, a test that analyzes biological and clinical […]

May 4, 2017 - 5 minutesmins - By External Contributor

News and Trends 3 May 2017

Immuno-oncology Pioneer Enters the Clinic with its RNA-based Therapy

Rigontec has announced the start if its first-in-human Phase I/II study with its pioneering RNA-based candidate, RGT100, in solid tumors and lymphoma. Rigontec, based in Munich, is exploring RNA’s applications in immuno-oncology. Since the company was founded in 2014, it has raked in an impressive €30M in series A funding. Now, only 3 years later, the biotech is […]

May 3, 2017 - 2 minutesmins - By Melanie De Almeida

More News! 3 May 2017

German Pharma Investigates Genetics of Pain to Personalize Treatment

At the height of the opioid epidemic, Grünenthal has partnered up with 23andMe to explore the genetic factors associated with pain. Though opioid abuse has not been as rampant in Europe as it has in the United States, German pharma Grünenthal, which focuses on pain, inflammation and gout, has staked out a position in the fight. Today, […]

May 3, 2017 - 3 minutesmins - By Evelyn Warner

News and Trends 3 May 2017

E-GUIDE: This is how you bring a molecule to the clinic

May 3, 2017 - 0 minutesmins - By External Contributor

News and Trends 3 May 2017

New Immuno-oncology Biotech Gets a €20M Series A Funding Boost

Imcheck Therapeutics from Marseille has just completed a €20M Series A funding round, backed by big investors like the Boehringer Ingelheim Venture Fund (BIVF). The French biotech Imcheck Therapeutics was founded in 2015 as a spin-off from the Paoli-Calmettes Cancer Institute (IPC) in Marseille and is developing next-generation immunomodulatory antibodies for the treatment of cancer and autoimmune diseases. […]

May 3, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 3 May 2017

French Biotech gets a Second Opportunity to Fight Liver Fibrosis

Genkyotex, a French biotech with an eye on NASH, has received FDA approval to initiate a Phase II trial in primary biliary cholangitis. Genkyotex’s lead candidate, GKT831, failed to prove its efficacy in a Phase II trial for diabetic nephropathy a couple of years ago. Now, the company is taking a second shot by targeting liver […]

May 3, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 May 2017

Unexpected Side Effects: Are we Ready for the Rise of Immunotherapies?

As immunotherapies are moving from large academic centers to clinics across the world, doctors are realizing that releasing the breaks of the immune system comes with serious risks – and that research on its adverse effects is lagging behind. This week, AstraZeneca’s anti-PD-L1 antibody durvalumab received FDA approval to treat patients with metastatic urothelial carcinoma, making […]

May 3, 2017 - 4 minutesmins - By Melanie De Almeida

Interview 2 May 2017

Video Interview: Meet the Inventor of the Surgical Super-glue

At our second meetup in Basel last week, Philip had the chance to talk to Maria Pereira, one of Forbes’ 30 under 30 and the scientific inventor of the technology behind Gecko Biomedical. Apart from telling us about Gecko’s progress and future plans, Maria talked about her time in Boston and why she ended up […]

May 2, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 2 May 2017

Novartis Gains Access to Celyad’s allogenic CAR-T cell patents

Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR-T cells in a non-exclusive license agreement, worth up to €88M. Celyad is developing “off-the-shelf” therapies, based on engineering donor-derived allogeneic T cells. Despite a recent public dispute with its key rival Cellectis regarding the validity of Celyad’s US patents, Novartis has now entered a non-exclusive […]

May 2, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 2 May 2017

French HIV Cure Reduces Viral Reservoirs for the First Time Ever

Abivax has announced results from a Phase IIa trial that reveal the first proof in human of viral load reduction of hidden HIV reservoirs. Abivax is developing a functional HIV cure that, unlike current antiretroviral therapy (ART), could completely eliminate the virus and prevent it from coming back when the treatment is stopped. Results from a Phase IIa […]

May 2, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

French Gene Therapy Biotech Raises a Huge €37.5M in Series A

Parent Bacteria Resist Antibiotics Better than their Offspring

This Belgian Startup is building the Next Generation of Diagnostic Tests

Immuno-oncology Pioneer Enters the Clinic with its RNA-based Therapy

German Pharma Investigates Genetics of Pain to Personalize Treatment

E-GUIDE: This is how you bring a molecule to the clinic

New Immuno-oncology Biotech Gets a €20M Series A Funding Boost

French Biotech gets a Second Opportunity to Fight Liver Fibrosis

Unexpected Side Effects: Are we Ready for the Rise of Immunotherapies?

Video Interview: Meet the Inventor of the Surgical Super-glue

Novartis Gains Access to Celyad’s allogenic CAR-T cell patents

French HIV Cure Reduces Viral Reservoirs for the First Time Ever

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!